Amigo Mike
3 weeks ago
A couple more Form 4s posted this evening for directors I believe completing the reporting on the laughable adjustments. I surely don't have any issue with directors being compensated and I know they were behind on it as explained in the filings .... but given the lack of .... frankly ... anything from this company in a while, there isn't much public justification for the awards. The Marchiando award ..... um ..... WTF. ZIVO don't need much more than a bookkeeper.
The Maggiore Form 4 shows he purchased over 3700 shares on the open market on June 12th but that many shares didn't trade so guessing he was almost all the action from June 10-12. Buying with Maggiore sometimes good .... sometimes not so good. In this case .... good news of an actual insider buy. On the flip side of that, he can't buy in front of or if in receipt of material news ...... so ... IMO, there isn't any significant news coming from ZIVO in the very short term. The cone of silence may have a purpose. The question is ... what ? I won't be buying with Maggiore here.
8K also posted. And frankly, scratching my head. Matter of fact vote results .... and that's it. No shareholder address for the annual meeting offered. No update on where the company is and where it is going.
Frankly, I am leaning heavily towards ZIVO selling to a big boy at this point. They've characterized the molecule and mechanism of action and have filed multiple patents. Last I checked I believe those patents surrounding these items were still in process. Payne while still an industry guy is well up there in age and there isn't an hier apparent to the ZIVO throne with the exception of Cornell who I think has the skillset to handle it ..... but Payne is the guy and it's his baby at this point. ZIVO has a shitload of loss carryforwards that have value as well ..... so gimme $25-$40 and lets move on already. Too cheap but ZIVO can't prove all the vertical options in a reasonable time and doesn't have the coin to do it ..... so it's time to get something done. That would be pocket change to a big boy animal pharma.
Amigo Mike
Tony53711
4 weeks ago
More incompetence rewarded. Free stock for nearly taking the share price to 0 in 2023 as a non-employee director. Capitalism at its finest.
“On June 5, 2024, the Reporting person accepted and was issued 81,544 shares of restricted stock in lieu of unpaid non-employee director service fees earned during the calendar year ending December 31, 2023. The Reporting Person was owed $53,819 and the unpaid amounts were grossed up for taxes at an assumed tax rate of 45% and the number of shares was determined based on the Issuer’s closing stock price on December 29, 2023 of $1.20 per share. Pursuant to his Restricted Stock Award Grant Notice, 50% of the granted shares vest immediately upon grant date and the remaining 50% of the shares will vest on January 1, 2025.”
Amigo Mike
1 month ago
LOL,
No explanation on the form which is a bit unusual. But given the annual shareholder meeting is next week, wouldn't shock me if this was first of multiple equity awards to directors.
Of course at ~$8 / share ..... amounts to near $300k award. Um, for what is known today, that is silly ass ridiculous unless there is more to it.
Speaking of which, everyone have their flight booked to Detroit to attend next week's meeting ? LOL. I should have gathered a couple troops and arranged a meet up but forgot about it. Oh well.
Amigo Mike